Previous close | 60.96 |
Open | 61.31 |
Bid | 62.38 x 400 |
Ask | 62.45 x 400 |
Day's range | 60.68 - 63.23 |
52-week range | 56.05 - 100.77 |
Volume | |
Avg. volume | 2,445,920 |
Market cap | 11.329B |
Beta (5Y monthly) | 1.23 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.13 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 90.66 |
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.